Monthly Archives: May 2023

At 25, Sierra Johnson feels good about working a full-time job, setting goals for herself, and looking forward to the future.

However, this wasnt always the case.

Just a few months ago, Sierra wouldnt leave her bedroom, let alone her house. She loved working with children but couldnt keep her job at a day care center.

Since she was a young teenager, Sierras anxiety and depression symptoms interfered with school, work, relationships, and life in general. So much so, she shut out the world and hid behind room-darkening curtains in her bedroom.

I was going down this path from fifth grade until now that I was just never happy, Sierra said. I gave up on everything. I became angry and paranoid, and did not get along with my family.

I blamed everyone else, she said. I was stuck.

TMS therapy a game changer

Sierra heard about a treatment called transcranial magnetic stimulation, better known as TMS.

TMS is an outpatient therapy that uses a device to give very short pulses of magnetic energy to stimulate nerve cells in certain parts of the brain, explained Dr. Lindsay Campbell, WellSpan psychiatrist and behavioral health site director.

The magnetic device stimulates the underactive parts of the brain in patients diagnosed with depression.

Its quite effective for those patients experiencing major depressive disorder and anxious depression, Dr. Campbell said.

Once patients are referred for TMS, Tanya Seprinski, WellSpan TMS coordinator, works to arrange their treatment plan and sessions. She also works with insurance companies to get patients approved for the program.

The therapy is quick, with sessions lasting just 18 to 20 minutes. Its also safe, with minimal side effects, and patients can drive afterward. Typically, after a few weeks, patients notice a difference, Seprinski explained.

More than 500 patients have turned to WellSpan for TMS therapy. The program, which is available in York and Mt. Gretna, has the lowest drop-out rate in the country.

Our program has changed in that we have implemented several new devices and protocols which translate into less time in the TMS chair for patients and improved accuracy, Dr. Campbell said.

A new outlook on life

For Sierra, once she committed to TMS, there was no turning back. She completed all her treatments over a few months.

At first, the changes in Sierra were subtle.

After treatment 10, my attitude had really changed, she said. And that brought on other, larger changes. I was able to get out of bed and leave my room. I had more energy.

Sierra started noticing physical and emotional changes in herself. Next, family relationships began to heal, and she was back to taking her medication daily without skipping.

I was so happy, I cried, she said. The cloud hanging over me was gone and I could face the day with positivity.

Since completing TMS, Sierra is back to working full-time at her day care job and has the confidence to shop alone and mingle at large events, no longer feeling the need to hide in her bedroom.

She is sharing her story on social media and has been interviewed by reporters from local TV stations - all with the goal of promoting hope for others with depression and anxiety.

I will always have a diagnosis of anxiety and depression, but now I am able to deal with it, she said.

Results of TMS therapy

Studies have shown TMS can improve depression symptoms in up to 83% of patients undergoing treatment, and 62% of them achieve symptoms of relief or remission from their depression.

In addition to depression, the FDA has also approved TMS for obsessive-compulsive disorder, migraines, and smoking cessation, although these are separate protocols than the ones used for depression.

To learn more about TMS therapy, visit WellSpan Philhaven, here.

View original post here:

TMS therapy: The cloud hanging over me was gone - WellSpan Health

Summary: Transcranial magnetic stimulation (TMS), a treatment involving strong magnetic pulses applied to the scalp, alleviates severe depression by reversing the flow of neural activity in the brain.

The treatment, known as Stanford neuromodulation therapy (SNT), modifies brain activity related to depression, with effects seen after 10 sessions over five days.

The research shows that in many patients with depression, neural signals between key areas of the brain are sent in the opposite direction to that of a normal brain, which changes after SNT. This abnormal flow of neural activity could serve as a biomarker for diagnosing depression.

Key Facts:

Source: Stanford

Powerful magnetic pulses applied to the scalp to stimulate the brain can bring fast relief to many severely depressed patients for whom standard treatments have failed. Yet its been a mystery exactly how transcranial magnetic stimulation, as the treatment is known, changes the brain to dissipate depression.

Now, research led by Stanford Medicine scientists has found that the treatment works by reversing the direction of abnormal brain signals.

The findings also suggest that backward streams of neural activity between key areas of the brain could be used as a biomarker to help diagnosedepression.

The leading hypothesis has been that TMS could change the flow of neural activity in the brain, said Anish Mitra, MD, Ph.D., a postdoctoral fellow in psychiatry andbehavioral sciences. But to be honest, I was pretty skeptical. I wanted to test it.

Mitra had just the tool to do it. As a graduate student at Washington University in Saint Louis, in the lab of Mark Raichle, MD, he developed a mathematical tool to analyzefunctional magnetic resonance imaging, or fMRIcommonly used to locate active areas in the brain. The new analysis used minute differences in timing between the activation of different areas to also reveal the direction of that activity.

In the new study, published May 15 in theProceedings of the National Academy of Sciences, Mitra and Raichle teamed up with Nolan Williams, MD, associate professor of psychiatry and behavioral sciences, whose team has advanced the use of magnetic stimulation, personalized to each patients brain anatomy, to treat profound depression.

The FDA-cleared treatment, known as Stanford neuromodulation therapy, incorporates advanced imaging technologies to guide stimulation with high-dose patterns of magnetic pulses that can modify brain activity related tomajor depression.

Compared with traditional TMS, which requires daily sessions over several weeks or months, SNT works on an accelerated timeline of 10 sessions each day for just five days.

This was the perfect test to see if TMS has the ability to change the way that signals flow through the brain, said Mitra, who is lead author of the study. If this doesnt do it, nothing will.

The researchers recruited 33 patients who had been diagnosed with treatment-resistant major depressive disorder. Twenty-three received SNT treatment, and 10 received a sham treatment that mimicked SNT but without magnetic stimulation. They compared data from these patients with that of 85 healthy controls without depression.

When they analyzed fMRI data across the whole brain, one connection stood out. In the normal brain, the anterior insula, a region that integrates bodily sensations, sends signals to a region that governs emotions, the anterior cingulate cortex.

You could think of it as the anterior cingulate cortex receiving this information about the bodylike heart rate or temperatureand then deciding how to feel on the basis of all these signals, Mitra said.

In three-quarters of the participants with depression, however, the typical flow of activity was reversed: Theanterior cingulate cortexsent signals to the anterior insula. The more severe the depression, the higher the proportion of signals that traveled the wrong way.

What we saw is that whos the sender and whos the receiver in the relationship seems to really matter in terms of whether someone is depressed, Mitra said.

Its almost as if youd already decided how you were going to feel, and then everything you were sensing was filtered through that, he said. The mood has become primary.

Thats consistent with how a lot of psychiatrists see depression, he added. Even things that are quite joyful to a patient normally are suddenly not bringing them any pleasure.

When depressed patients were treated with SNT, the flow of neural activity shifted to the normal direction within a week, coinciding with a lifting of their depression.

Those with the most severe depressionand the most misdirected brain signalswere the most likely to benefit from the treatment.

Were able to undo the spatio-temporal abnormality so that peoples brains look like those of normal, healthy controls, Williams said.

A challenge of treating depression has been the lack of insight into its biological mechanisms. If a patient has a fever, there are various testsfor a bacterial or viral infection, for examplethat could determine the appropriate treatment. But for a patient with depression, there are no analogous tests.

This is the first time in psychiatry where this particular change in a biologythe flow of signals between these two brain regionspredicts the change in clinical symptoms, Williams said.

Not everyone with depression has this abnormal flow of neural activity, and it may be rare in less severe cases of depression, Williams said, but it could serve as an important biomarker for triaging treatment for the disorder.

The fMRI data that allows precision treatment with SNT can be used both as a biomarker for depression and a method of personalized targeting to treat its underlying cause, he said.

When we get a person with severe depression, we can look for this biomarker to decide how likely they are to respond well to SNT treatment, Mitra said.

Behavioral conditions like depression have been difficult to capture with imaging because, unlike an obvious brain lesion, they deal with the subtlety of relationships between various parts of the brain, said Raichle, who has studied brain imaging for more than four decades.

Its incredibly promising that the technology now is approaching the complexity of the problems were trying to understand.

The researchers plan to replicate the study in a larger group of patients. They also hope others will adopt their analytic technique to uncover more clues about the direction ofbrain activityhidden in fMRI data. As long as you have good clean fMRI data, you can study this property of the signals, Mitra said.

Author: Nina BaiSource: StanfordContact: Nina Bai StanfordImage: The image is credited to Neuroscience News

Original Research: Open access.Targeted neurostimulation reverses a spatiotemporal biomarker of treatment-resistant depression by Anish Mitra et al. PNAS

Abstract

Targeted neurostimulation reverses a spatiotemporal biomarker of treatment-resistant depression

Major depressive disorder (MDD) is widely hypothesized to result from disordered communication across brain-wide networks. Yet, prior resting-state-functional MRI (rs-fMRI) studies of MDD have studied zero-lag temporal synchrony (functional connectivity) in brain activity absent directional information.

We utilize the recent discovery of stereotyped brain-wide directed signaling patterns in humans to investigate the relationship between directed rs-fMRI activity, MDD, and treatment response to FDA-approved neurostimulation paradigm termed Stanford neuromodulation therapy (SNT).

We find that SNT over the left dorsolateral prefrontal cortex (DLPFC) induces directed signaling shifts in the left DLPFC and bilateral anterior cingulate cortex (ACC).

Directional signaling shifts in the ACC, but not the DLPFC, predict improvement in depression symptoms, and moreover, pretreatment ACC signaling predicts both depression severity and the likelihood of SNT treatment response.

Taken together, our findings suggest that ACC-based directed signaling patterns in rs-fMRI are a potential biomarker of MDD.

See more here:

Depression Relief: Brain Signal Reversal by Magnetic Pulses - Neuroscience News

Revolutionizing Depression Treatment: HWS Center Brings Advanced TMS Therapy to New Jersey Residents

TMS Therapy is a non-invasive procedure that utilizes magnetic fields to stimulate specific areas of the brain. This stimulation helps regulate brain activity and alleviate symptoms associated with depression. TMS Therapy has shown remarkable success in improving the quality of life for patients who have not achieved satisfactory results from antidepressant medications or other treatment modalities.

With the launch of TMS Therapy New Jersey at HWS Center, residents of New Jersey now have access to this cutting-edge treatment option closer to home. Previously, individuals seeking TMS Therapy had to travel long distances, often out of state, to receive this specialized treatment. The HWS Center's commitment to delivering mental health care services led to the introduction of TMS Therapy, ensuring that patients in New Jersey can access innovative treatments without the burden of extensive travel.

HWS Center is experienced in providing TMS Therapy and is dedicated to delivering personalized care to each patient. Led by a team of renowned psychiatrists, the HWS Center combines expertise, advanced technology, and a patient-centered approach to create a supportive environment for individuals seeking mental health treatment.

"We are thrilled to introduce TMS Therapy at HWS Center," said Dr. Yuli Fradkin, Founder at HWS Center. "This ground-breaking treatment offers a new ray of hope for individuals who have not found relief through traditional methods. Our goal is to provide mental health care services to the community, and the addition of TMS Therapy allows us to expand our offerings and help more individuals on their journey to recovery."

Individuals interested in TMS Therapy can schedule a consultation with the specialists at HWS Center to determine their eligibility and explore personalized treatment options. The HWS Center team is committed to providing exceptional care, ensuring patient comfort, and supporting individuals throughout their treatment journey.

For more information about TMS Therapy and the comprehensive mental health services offered at HWS Center, please visit https://hwscenter.com/ or contact 201-500-9728 for inquiries and appointment scheduling.

About HWS Center HWS Center, located in New Jersey, is a leading healthcare facility dedicated to providing innovative and transformative treatments for mental health conditions and neurological disorders. With a multidisciplinary team of experts, they specialize in Transcranial Magnetic Stimulation (TMS) therapy, Ketamine infusion therapy, and cutting-edge treatments for Autism Spectrum Disorder (ASD). In this blog post, we will explore the exceptional services offered by HWS Center, shedding light on their commitment to improving lives and fostering holistic well-being.

Read More https://hwscenter.com/

YULI FRADKINHWS Center+1 201-500-9728email us hereVisit us on social media:FacebookTwitterLinkedIn

Read more from the original source:

HWS CENTER LAUNCHES TMS THERAPY, BRINGING CUTTING-EDGE MENTAL HEALTH TREATMENT TO NEW JERSEY - EIN News

May 15Future Tahlequah Middle School students roamed the halls of the sixth- through eighth-grade site last Tuesday, May 9.

During the morning of May 9, fifth-grade students with Tahlequah Public Schools toured the building by themselves, while later that night, the soon-to-be sixth-graders guided their parents through the halls.

TMS Principal Abby Keys said the morning and night tours offer incoming students a way to get acclimated to the building. By having the kids walk the halls a few hours before the night tours, Keys said, students gets a sense of pride and ownership as they take their parents on the same walk.

"We want our kids to come first and then they can bring their families," said Keys. "It's a big change from being in elementary. It's a lot bigger, and all of them are coming in together, so it gives them their first little taste of all being together here."

The morning event, which only featured the incoming students, had the kids walking the halls and receiving information on classes they will be taking, while a more in-depth version was given during the evening tour.

Keisha Murray, an event attendee, brought her home-schooled daughter, Emersyn Murray, as she did not get participate in the morning tours. Emersyn said the tour helped take away some of the scariness surrounding the upcoming year.

Shayna Rodriguez, a parent at the evening tour, said she already knew the layout of the school from subbing at TMS. Since Shayna already knew the lay of the land, she had her son, Liam Rodriguez, show her where he will be going each day. She said the fact that her son already knew how to make his way to his locker and classes was reassuring.

"His summer school is going to be done here, so that alone made my anxiety go out the window, because I knew he has all month of June to prepare [as well]," said Shayna.

Keisha said the event also answered her family's main questions regarding electives and how they work.

Story continues

"We knew there were some, but we didn't know how they get chosen or anything like that," said Keisha.

Keys said she hopes the tours allowed parents and students to feel less anxious about that big step from elementary to middle school. The event offered guardians and their children a chance to ask questions.

"I think it just answers a lot of questions for them," said Keys. "If they have questions about electives, or they have questions here within the school, we're all here tonight to be able to help them."

TMS music director Amy Wright said she's noticed the tours have reassured not only the incoming sixth-graders but the parents, as well.

"I think it is comforting for the kids to be able to see the teachers' faces before they get here, and that it's good for the parents to know we are here to help their children succeed, because all we remember is what we went through in middle school and how horrible it was," said Wright. "It just [helps them to] know there's going to be those times, but we're here for their kids."

See the article here:

Incoming TMS students take tours of site - Yahoo News

Almost 17 years ago in a garage in Southern California, Todd Harrison started one of the most widely recognized and respected titanium supply businesses in the country, TMS Titanium. Like so many racing dreams it began with a young man reading issues of Hot Rod magazine and having a goal.

I had read an article in Hot Rod magazine about titanium connecting rods, said Harrison. I worked for a guy who was a racer and I started asking him titanium questions. The next thing I knew I had a job offer. I worked for them and grew that company. I moved from there to another titanium processing company as their general manager. I decided to go out on my own in 2006 in my parents garage.

The early years were not easy as titanium costs were sky high, but Harrison had passion and knew how he would set his company apart. He focused on customer service and finding loyal customers. That combination along with hard work has set Harrison on a path that has seen TMS Titanium grow every year and provide high-quality titanium to customers in just about every racing series as well as aerospace, tactical operations, the chemical and medical industries, and marine services. The biggest growth area for the company has been racing and especially drag racing.

Our sales staff is really plugged in to the racing world professionally and personally, Harrison said. They are fans and they want to do a good job. They know this is a performance business and they like to see the teams we work with win races and championships. We were fortunate to work with Elite Motorsports and Ron Capps Motorsports, who won NHRA Pro Stock and Funny Car championships in 2023. We were involved in supplying the titanium for some of the performance enhancement they made. It is a great feeling to see your friends win and dominate. It was special to be a part of Ron Capps first championship as a new team owner. I spent a lot of time talking with (Capps crew chief) Dean Antonelli talking about parts and uses of titanium.

Harrison isnt just interested in the bold type names in drag racing. He and TMS Titanium are great supporters of up-and-coming teams. He remembers how hard it was to get his company started and it took a lot of support and encouragement from friends and associates. He considers every client a friend and no matter what level they are racing, they should get the best customer service and attention possible.

We are working with Jason Rupert, who is a six-time champion in [nostalgia] Funny Car. He is stepping up to the NHRA Nitro Funny Car class and he just needs some help. We offer material, guidance, and marketing partnerships. We figured out a way to jump in and help some of these smaller teams. We want them to succeed, be competitive, and be safe. Jason is a very interesting relationship. Not only is he a six-time champion but he is also a welder and fabricator. He really understands the metal and I have learned things about titanium from our conversations about his applications and what he has seen and experienced over the years.

One of the benefits TMS Titanium brings to the racing industry is their relationships outside of the sport. Harrison and his partner, James Hostetler, develop contacts with companies and industries around the world. The cross-over from the aerospace, medical, and tactical fields has been a game changer for the company over the years.

These industries are really one and the same. They speak the same language, and they speak a completely different language at the same time. We have people that have no interest in racing, but they are having the exact same problem a race team is having. I can use my knowledge of seeing broken parts and machining applications in the racing world and take that information to the aerospace or chemical processing or medical world and we are able to provide answers and solve problems for them. Everyone struggles at times, whether its racing or machining, and we try and do our little bit to help teams and organizations use our products and our knowledge base. I have always said customer service is No. 1. You must be able to be there for the customer. If you dont know the answer right then let them know you will find out and get right back to them as soon as you can.

Over the years Harrison has met and worked with many legends in the sport. Most importantly, he has developed long-term relationships with some of the biggest names in drag racing. He has leaned on them for advice both in the business and racing worlds.

I have been trained by Roland Leong, who is a great mentor of mine. He has always said it is not what you know, it is who you know. Through our relationships across different racing series from SRX to NASCAR to IndyCar to NHRA, we have created relationships with this knowledge base. If we dont have the answer, I can go to a contact at another organization and get input from them.

Like any business, there have been good years and lean years. Most recently, the past two to three years have been especially trying with a pandemic and global conflict upending supply chains and logistical networks. This is where the long-standing mindset of customer service first has served Harrison and TMS Titanium well to manage a shifting global economy.

We have had a good supply chain for 16 years now, Harrison said. The biggest impact we have seen besides just the world economy and Covid has been the Russian-Ukraine war. A lot of material came from that part of the world. Fifty percent of Boeings aerospace material came out of Russian mills for commercial aerospace, and that has changed with the impact of the war. There is also metal that was melted in Ukraine and shipped to the US to be manufactured, and all those situations have changed. We have had to be very creative in our relationships and luckily, we have some very loyal mills that we work with and suppliers that understand our business. We have found some workarounds and we have been able to continue to work because they know we have great customer service and we do a good job.

Working in the racing industry has been a dream come true for Harrison. While he is not hands on day-to-day with a team or car, he is as involved as he can be. His customers in every industry know he is a phone call or text away. In racing, that can mean contact at any hour of the day. These are the moments and situations Harrison and TMS Titanium thrive in and are eager to step up to help.

We get emails and calls non-stop around the clock, Harrison said. Racers work in the middle of the night. They are in the garage and we get those calls or texts. We just try and be available and fulfill as many of them as possible. It is neat to get a text at 9:30 p.m. and you can give someone an answer and you get into the office at 6:00 a.m. and it gets shipped right out. That is a great relationship to have with these guys.

I cant tell you how many times we get a call two or three days before a race where a racer needs something, Harrison continued. A great example is Ryan Martin blew up his transmission and threw the driveshaft out. They called us at 3:40 p.m. and we stopped production. I put six guys on an eight line item order and we got it out UPS red so he got it the next day, put the car together, and was able to continue filming his racing.

With racing growing and getting faster every season, TMS Titanium and Harrison have kept up their end of the bargain. They are always available and will put in the work to support any race team at any level. They work round the clock to source materials and solve problems whether a team needs to fix a Funny Car body support or a medical fabricator needs raw materials to design a new titanium rod for a patient. The goal is getting the win and keeping the customer happy.

Related

See the original post:

Passion Drives TMS Titanium's Todd Harrison - Drag Illustrated

- Positive results from two studies reconfirm safety and efficacy of Focal One -

- Company to host conference call and webcast today, Wednesday, May 17that 8:30 am EDT -

LYON, France, May 17, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter ended March 31, 2023.

"After achieving record results in the fourth quarter of 2022, we continued to see growing demand through the first quarter of 2023, with our strongest Q1 revenue performance on record," said Ryan Rhodes, Chief Executive Officer of EDAP. "We placed seven Focal One units, including six equipment sales and one operating lease. Based upon the positive feedback from urologists, particularly at this year's recent EAU & AUA meetings, we expect momentum for the Focal One platform to continue throughout 2023, driven by our state-of-the-art technology, our positive clinical outcomes demonstrating excellent oncologic control, and our world-class sales and customer support team."

"Beyond our commercial performance, we also announced positive results from two clinical studies utilizing Focal One, both conducted at leading academic urology centers. Results from these studies clearly demonstrate the safety, efficacy, and benefits of Focal One that support both continued growth and increased utilization of the technology. As Focal One continues to grow, we are also making commercial progress in other areas. We recently received approval of ExactVuTM micro-ultrasound in Japan, representing a significant regulatory milestone for EDAP that introduces this innovative platform to the world's second largest medical device market. As we continue to invest in expanding both clinical and commercial activities to drive bottom line performance, we maintain a strong cash position to support both short and long-term growth."

Business Update:

First Quarter 2023 Results

Total revenue for the first quarter 2023 was EUR 14.8 million (USD 15.9 million), an increase of 13.8% as compared to total revenue of EUR 13.0 million (USD 14.5 million) for the same period in 2022.

Total revenue in the HIFU business for the first quarter 2023 was EUR 5.3 million (USD 5.7 million), an increase of 39.5% as compared to EUR 3.8 million (USD 4.3 million) for the first quarter of 2022. The increase was driven by six Focal One units sold in the first quarter 2023 versus four units sold in the first quarter 2022.

Total revenue in the LITHO business for the first quarter 2023 was EUR 2.8 million (USD 3.0 million), as compared to EUR 2.2 million (USD 2.5 million) for the first quarter of 2022. The improvement was driven by four lithotripsy unit sold in the first quarter of 2023 as compared to one unit sold in the first quarter of 2022.

Total revenue in the Distribution business for the first quarter 2023 was EUR 6.8 million (USD 7.3 million), as compared to EUR 7.0 million (USD 7.8 million) for the first quarter of 2022. The decrease was driven primarily by eight ExactVu units sold during the first quarter of 2023 as compared to nine units sold during the first quarter of 2022.

Gross profit for the first quarter 2023 was EUR 6.0 million (USD 6.5 million), compared to EUR 5.8 million (USD 6.4 million) for the year-ago period. Gross profit margin on net sales was 40.8% in the first quarter of 2023, compared to 44.3% in the year-ago period. The decrease in gross profit rate year-over-year was primarily due to investments in service and applications in the U.S.

Operating expenses were EUR 12.6 million (USD 13.6 million) for the first quarter of 2023, compared to EUR 5.9 million (USD 6.6 million) for the same period in 2022. The significant increase in operating expenses is mainly due to the ongoing build-out of the U.S. team and commercial infrastructure, and non-recurring expenses linked to the leadership succession plan.

Operating loss for the first quarter of 2023 was EUR 6.6 million (USD 7.1 million), compared to an operating loss of EUR 0.1 million (USD 0.1 million) in the first quarter of 2022.

Net loss for the first quarter of 2023 was EUR 7.5 million (USD 8.1 million), or EUR 0.2 per diluted share, as compared to net income of EUR 0.4 million (USD 0.4 million), or EUR 0.01 per diluted share in the year-ago period.

As of March 31, 2023, the company held cash and cash equivalents of EUR 58.3 million (USD 63.4 million) as compared to EUR 63.1 million (USD 67.5 million) as of December 31, 2022.

Conference Call

A conference call and webcast to discuss first quarter 2023 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, Franois Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary, today Wednesday, May 17th, 2023 at 8:30am EDT. Please refer to the information below for conference call dial-in information and webcast registration.

About the Endo-HIFU-R1 Phase 2 Study

The Endo-HIFU-R1 Phase 2 study was designed and conducted to evaluate the safety and efficacy of therapeutic high-Intensity focused ultrasound (HIFU) for the treatment of rectal endometriosis with EDAP's Focal One Robotic HIFU device. At six-months follow up, of the 60 patients enrolled and treated with Focal One HIFU across four centers in France between August 2020 and March 2022, 96.7% demonstrated positive safety with no or non-significant adverse events (Clavien 1), 3.3% presented Clavien 2 complications and zero patients presented Clavien 3 complications. Additional endpoints included evaluation of the effect of HIFU treatment on endometriosis symptoms and Quality of Life (QoL). A significant decrease in endometriosis symptom level (acute pelvic pain, dyspareunia, diarrhea, constipation, rectal bleeding, false urges, tenesmus, rectal spams, posterior pelvic pain and asthenia) and an improvement in almost all evaluated QoL criteria (physical functioning, role limitation due to emotional problems, energy - fatigue, emotional well-being, social functioning, bodily pain, general health, and on physical and mental global score components) were observed at the first post-treatment evaluation at one month, and those benefits were maintained at three and six months following HIFU treatment. The study also blindly evaluated the evolution of nodule volume via MRI, with a significant reduction of the volume of lesions observed at six months. Results from the study were presented by study coordinator, Pr. Gil Dubernard of Croix Rousse University Hospital (Lyon, France) at the Paris Sant Femmes French Congress on Friday, January 27, 2023.

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and http://www.focalone.com.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the "Securities Act") or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as "believe," "can," "contemplate," "could," "plan," "intend," "is designed to," "may," "might," "potential," "objective," "target," "project," "predict," "forecast," "ambition," "guideline," "should," "will," "estimate," "expect" and "anticipate," or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.

Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.

Company Contact

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 50

bconfort@edap-tms.com

Investor Contact

John Fraunces

LifeSci Advisors, LLC

(917) 355-2395

jfraunces@lifesciadvisors.com

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands of Euros and U.S. Dollars, except per share data)

NOTE: Translated for convenience of the reader to U.S. dollars at the 2023 average three months' noon buying rate of 1 Euro = 1.0777 USD, and 2022 average three months noon buying rate of 1 Euro = 1.1177 USD

EDAP TMS S.A.

UNAUDITED CONSOLIDATED BALANCE SHEETS HIGHLIGHTS

(Amounts in thousands of Euros and U.S. Dollars)

NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.0872 USD, on March 31, 2023 and at the noon buying rate of 1 Euro = 1.0697 USD, on December 31, 2022.

EDAP TMS S.A.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands of Euros)

(1) including share based compensation expenses for 2,660 thousand of Euros for the three months ended March 31, and 2,103 thousand of Euros for the full year ended December 31, 2022.

NOTE: Translated for convenience of the reader to U.S. dollars at the 2023 average three months' noon buying rate of 1 Euro = 1.0777 USD, and 2022 average twelve months noon buying rate of 1 Euro = 1.0519 USD

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

three months ended March 31, 2023

(Amounts in thousands of Euros)

Disclaimer

Edap TMS SA published this content on 17 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 May 2023 10:40:10 UTC.

Publicnow 2023

Technical analysis trends EDAP TMS S.A.

Income Statement Evolution

Go here to read the rest:

EDAP TMS S A : Positive results from two studies reconfirm safety ... - Marketscreener.com